Artelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th
Artelo Biosciences (NASDAQ: ARTL) will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Artelo Biosciences (NASDAQ: ARTL) will present at the H.C. Wainwright Life Sciences Conference, scheduled for March 9-10, 2021. Gregory Gorgas, CEO, will provide insights on the company's development of therapeutics targeting the endocannabinoid system. The presentation will be available on-demand from March 9 at 7:00 AM Eastern Time on the conference platform. Additionally, Artelo's management will hold one-on-one meetings with qualified investors during the event, highlighting its focus on addressing unmet needs in various diseases.
Details
News Market Reaction – ARTL
The recorded move for ARTL in the trading session of this news was -6.10%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LA JOLLA, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, Chief Executive Officer of Artelo Biosciences, will be presenting at the H.C. Wainwright Life Sciences Conference to be held virtually between March 9-10, 2021.
Artelo’s presentation will be available on-demand to registered attendees via the conference platform beginning Tuesday, March 9, 2021 at 7:00 AM Eastern Time. The webcast can be accessed here and on the investor relations section of Artelo's website at https://ir.artelobio.com/. Management will also be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
About Artelo Biosciences
Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting endogenous signaling pathways, including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.